Print

RetroSense Therapeutics Completes pre-IND Meeting for RST-001  
5/24/2012 10:15:50 AM

ANN ARBOR, Mich.--(BUSINESS WIRE)--RetroSense Therapeutics, a gene therapy company dedicated to vision restoration, announced completion of a pre-IND meeting with the Center for Biological Evaluation and Research (CBER) division of the FDA that took place on May 22nd 2012 regarding RetroSense’s lead biologic, RST-001 for vision restoration in retinal degenerative conditions.